Preparation of insulin loaded PLGA-Hp55 nanoparticles for oral delivery

Journal of Pharmaceutical Sciences

Volumn 96, Issue 2, 2007, Pages 421-427

  Cui, Fu De ^a   Tao, An Jin ^a   Cun, Dong Mei ^a   Zhang, Li Qiang ^a   Shi, Kai ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Nanoparticles; Oral absorption; Oral drug delivery; Peptide delivery; Poly(lactic acid) PLA; Poly(lactide co glycolide) PLGA

Indexed keywords

DRUG CARRIER; GLUCOSE; INSULIN; NANOPARTICLE; POLYGLACTIN; POLYGLACTIN HP55; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; DIABETES MELLITUS; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG FORMULATION; DRUG RELEASE; DRUG SYNTHESIS; EMULSION; ENCAPSULATION; GLUCOSE BLOOD LEVEL; HYPOGLYCEMIA; INSULIN RELEASE; MALE; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; RAT; STOMACH JUICE;

EID: 33847666114     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20750     Document Type: Article

References (24)

1. Chien YW. 1996. Human insulin: Basic sciences to therapeutic uses. Drug Dev Ind Pharm 22:753 789.
2. Schilling RJ, Mitra AK. 1990. Intestinal mucosal transport of insulin. Int J Pharm 62:53-64.
3. Maincent P, Thouvenot P, Amicabile C, Hoffman M, Kreuter J, Couvreur P, Devissaguet JP. 1992. Lymphatic targeting of polymeric nanoparticles after intraperitoneal administration in rats. Pharm Res 9:1534-1539.
4. Florence AT. 1997. The oral absorption of micro-and nanoparticulates: Neither exceptional nor unusual. Pharm Res 14:259-266.
5. Florence AT, Hussain N. 2001. Transcytosis of nanoparticle and den-drimer delivery systems: Evolving vistas. Adv Drug Deliv Rev 50:869-889.
6. Kawashima Y, Yamamoto H, Takeuchi H, Hino T, Niwa T. 1998. Properties of a peptide containing DL- lactide/glycolide copolymer nanospheres prepared by novel emulsion solvent diffusion methods. Eur J Pharm Biopharm 45:41-48.
7. Lamprecht A, Ubrich N, Hombreiro PM, Lehr CM, Hoffman M, Maincent P. 1999. Biodegradable monodispersed nanoparticles prepared by pressure homogenization-emulsification. Int J Pharm 184:97-105.
8. Barichello JM, Morishita M, Takayama K, Nagai T. 1999. Encapsulation of hydrophilic and lipophilic drugs in PLGA nanoparticles by the nanoprecipitation method. Drug Dev Ind Pharm 25:471-476.
9. Deepali D, William RR, Guru VB. 2003. Delivery of didanosine from enteric-coated, sustained-release bioadhesive formulation. Drug Deliv 10:47-50.
10. Tozaki H, Komoike J, Tada C, Maruyama T, Terabe A, Suzuki T, Yamamoto A, Muranishi S. 1997. Chitosan capsules for colon-specific drug delivery: Improvement of insulin absorption from the rat colon. J Pharm Sci 86:1016-1021.
11. Torres D, García-Encina G, Seijo B, Vila Jato JL. 1995. Formulation and in vitro evaluation of HPMCP-microencapsulated drug-resin complexes for sustained release of diclofenac. Int J Pharm 121:239-243.
12. Zaniboni HC, Fell JT, Collett JH. 1995. Production and characterisation of enteric beads. Int J Pharm 125:151-155.
13. Qi R, Ping QN. 2004. Gastrointestinal absorption enhancement of insulin by administration of enteric microspheres and SNAC to rats. J microencapsul 21:37-45.
14. Kawashima Y, Yamamoto H, Takeuchi H, Fujioka S, Hino T. 1999. Pulmonary delivery of insulin with nebulized DL-lactide/glycolide copolymer (PLGA) nanospheres to prolong hypoglycemic effect. J Control Rel 62:279-287.
15. Thirumala G, Snjezana S, Martin CG, Lisbeth I, Stanley SD. 1999. PLGA nanoparticles prepared by nanoprecipitation: Drug loading and release studies of a water soluble drug. J Control Rel 57:171-185.
16. Maurizio R, Carmelo P, Francesco B, Caterina DG, Stefano G, Carlo R. 2005. Evaluation of indomethacin percutaneous absorption from nanostructured lipid carriers: In vitro and in vivo studies. J Pharm Sci 94:1149-1159.
17. Morishita I, Morishita M, Takayama K, Machida Y, Nagai T. 1992. Hypoglycemic effect of novel oral microspheres of insulin with protease inhibitor in normal and diabetic rats. Int J Pharm 78:9-16.
18. Paquot M, Scheen AJ, Franchimont P, Lefebvre PJ. 1988. The intra-nasal administration of insulin induces significant hypoglycemia and classical counterregulatory hormonal responses in normal man. Diabetes Metab 14:31-36.
19. Takeuchi H, Yamamoto H, Kawashima Y. 2001. Mucoadhesive nanoparticulate systems for peptide drug delivery. Adv Drug Deliv Rev 47:39-54.
20. Mesiha M, Plakogiannis F, Vejosoth S. 1994. Enhanced oral absorption of insulin from desolvated fatty acid-sodium glycocholate emulsions. Int J Pharm 111:213-216.
21. Yamamoto A, Taniguchi T, Rikyuu K, Tsuji T, Fujita T, Murakami M, Muranishi S. 1994. Effects of various protease inhibitors on the intestinal absorption and degradation of insulin in rats. Pharm Res 11:1496-1500.
22. Morishita I, Morishita M, Takayama K, Machida Y, Nagai T. 1993. Enteral insulin delivery by microspheres in three different formulations using Eudragit L100 and S100. Int J Pharm 91:29-37.
23. Carino GP, Jacob JS, Mathiautz E. 2000. Nanosphere based on oral insulin delivery. J Control Rel 65:261-269.
24. Allemann E, Doelker E, Gurny R. 1993. Drug loaded poly(lactic acid) nanoparticles produced by a reversible salting-out process: purification of an injectable dosage form. Eur J Pharm Biopharm 39:13-18.